SRR10900564
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- ALLOGRAFT_REJECTION+0.300
- ANDROGEN_RESPONSE+0.300
- COMPLEMENT+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ADIPOGENESIS+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- KRAS_SIGNALING_DN-0.300
- MYC_TARGETS_V1-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- APICAL_JUNCTION-0.200
- MYOGENESIS-0.200
- PANCREAS_BETA_CELLS-0.200
- UV_RESPONSE_UP-0.200
- ANGIOGENESIS-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ad9039cd-cacc-43f3-8cc1-9a6af5d39e6f | — | — | 0.792 |
| 2 | ERR2208956 | — | — | 0.785 |
| 3 | 82962 | EPN | Supratentorial EPN | 0.776 |
| 4 | TCGA-OR-A5JV-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.775 |
| 5 | MNG464 | — | — | 0.771 |
| 6 | TCGA-55-8089-01A-11R-2241-07 | — | cohortA1 | 0.770 |
| 7 | BS_V72GX2AZ | low-grade glioma | — | 0.765 |
| 8 | DRR168557 | — | — | 0.763 |
| 9 | TCGA-44-6145-01A-11R-1755-07 | — | cohortA1 | 0.759 |
| 10 | BS_3MYEMXPQ | Med | Medulloblastoma | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |